DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome1 Completion of randomization marks another important milestone for the global Phase III DEEp program, with...
Hence then, the article about lundbeck announces last patient randomized in deep sea a phase iii trial of bexicaserin in dravet syndrome was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome )
Also on site :
- Anthropologie’s Multicolored Glass and Stone Hoops Add Vintage-Style Elegance to Any Look for Just $30
- Pulitzer-Winning Author’s Novel, Written in a Home Basement, Ranked ‘Greatest Book of the Last 20 Years’
- Taylor Swift Makes Surprise Emmys Cameo to Unpack Swiftie-Coded Easter Eggs With Detective Olivia Benson